graphpad prizm 8.4 Search Results


graphpad prizm 8.4  (GraphPad Software Inc)
90
GraphPad Software Inc graphpad prizm 8.4
Graphpad Prizm 8.4, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/graphpad prizm 8.4/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
graphpad prizm 8.4 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anova test  (GraphPad Software Inc)
90
GraphPad Software Inc anova test
Administration of 5F5, 2G6, or 3C11 monoclonal anti-N-methyl-D-aspartate receptor (NMDAR) antibodies precipitated seizures in mice. (A) Seizure burden was similar in 5F5 ( n = 15, red circles), 2G6 ( n = 12, blue circles) and 3C11 ( n = 12, green circles) antibody-treated groups. Data are median total seizure counts in 2 weeks. ** p < 0.01, <t>ANOVA</t> <t>with</t> <t>Dunnett’s</t> multiple comparisons tests; open cycles, 1X antibodies; filled cycles, 10X antibodies. (B) The distribution of cumulative seizure counts in all anti-NMDAR antibody-treated groups. *** p < 0.001, t -test. (C) Time to the first seizure was not different between the four treatment groups ( p = 0.39, Kruskal-Wallis test). Data are median latencies. Note log scale on Y axis.
Anova Test, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anova test/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
anova test - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Administration of 5F5, 2G6, or 3C11 monoclonal anti-N-methyl-D-aspartate receptor (NMDAR) antibodies precipitated seizures in mice. (A) Seizure burden was similar in 5F5 ( n = 15, red circles), 2G6 ( n = 12, blue circles) and 3C11 ( n = 12, green circles) antibody-treated groups. Data are median total seizure counts in 2 weeks. ** p < 0.01, ANOVA with Dunnett’s multiple comparisons tests; open cycles, 1X antibodies; filled cycles, 10X antibodies. (B) The distribution of cumulative seizure counts in all anti-NMDAR antibody-treated groups. *** p < 0.001, t -test. (C) Time to the first seizure was not different between the four treatment groups ( p = 0.39, Kruskal-Wallis test). Data are median latencies. Note log scale on Y axis.

Journal: Frontiers in Neuroscience

Article Title: Monoclonal Antibodies From Anti-NMDA Receptor Encephalitis Patient as a Tool to Study Autoimmune Seizures

doi: 10.3389/fnins.2021.710650

Figure Lengend Snippet: Administration of 5F5, 2G6, or 3C11 monoclonal anti-N-methyl-D-aspartate receptor (NMDAR) antibodies precipitated seizures in mice. (A) Seizure burden was similar in 5F5 ( n = 15, red circles), 2G6 ( n = 12, blue circles) and 3C11 ( n = 12, green circles) antibody-treated groups. Data are median total seizure counts in 2 weeks. ** p < 0.01, ANOVA with Dunnett’s multiple comparisons tests; open cycles, 1X antibodies; filled cycles, 10X antibodies. (B) The distribution of cumulative seizure counts in all anti-NMDAR antibody-treated groups. *** p < 0.001, t -test. (C) Time to the first seizure was not different between the four treatment groups ( p = 0.39, Kruskal-Wallis test). Data are median latencies. Note log scale on Y axis.

Article Snippet: Seizure burden, locomotor activity, and anxiety scores in each treatment group were expressed as median total seizure counts over 2-weeks of infusion, total distance traveled and percent time spent in the center, respectively and the groups were compared using the one-way analysis of variance (ANOVA) test followed by Dunnett’s multiple comparison tests (GraphPad Prizm 8.4, San Diego, CA).

Techniques: